Status:
COMPLETED
BMS-599626 in Patients With Advanced Solid Malignancies
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Cancer
Metastases
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 d...
Eligibility Criteria
Inclusion
- Diagnosis of metastatic cancer that has progressed on currently available therapies;
- At least 3 month life expectancy;
- Primary cancer must be solid (non-hematologic);
- Adequate bone marrow, liver \& kidney function;
- Negative pregnancy test.
Exclusion
- Serious, uncontrolled medical disorder;
- Individuals not willing or able to use an acceptable method to avoid pregnancy for the entire study period and for at least 3 months after the study;
- Pregnant or breastfeeding women;
- Patients with known brain metastasis;
- Uncontrolled or significant cardiovascular disease;
- Anticancer therapy within 2-6 weeks prior to study drug (depending on the therapy)
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00095537
Start Date
March 1 2004
Last Update
March 2 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Scottsdale, Arizona, United States
2
Local Institution
Tucson, Arizona, United States
3
Local Institution
Los Angeles, California, United States